Verónica Andreoli

Prof. Dr. Verónica Andreoli

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2024 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
MLMarco Lincango
Marco Lincango
VAVerónica Andreoli
Verónica Andreoli
HRHernán García Rivello
Hernán García Rivello
ABAndrea Bender
Andrea Bender
ACAna I Catalán
Ana I Catalán
CBCarolina B. Belli
Carolina B. Belli
Marco Lincango, M.S., Verónica Andreoli, Ph.D., Hernán García Rivello, Ph.D., Andrea Bender, Biochem., Ana I Catalán, M.S., Marilina Rahhal, Biochem., Rocío Delamer, Biochem., Mariana Asinari, Biochem., Adrián Mosquera Orgueira, Ph.D., María Belén Castro, M.D., María José Mela Osorio, M.D., Alicia Navickas, M.D., Sofia Grille, Ph.D., Evangelina Agriello, Biochem., Jorge Arbelbide, M.D., Ana Lisa Basquiera, Ph.D., and Carolina B Belli, Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2024.0089

2 June 2025 in Genes
Verified
Journal Article
Open access
PDF file
ABAna Lisa Basquiera
Ana Lisa Basquiera
VAVerónica Andreoli
Verónica Andreoli
SGSofía Grille
Sofía Grille
CBCarolina B. Belli
Carolina B. Belli
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematological malignancies characterized by ineffective hematopoiesis, resulting in cytopenias, morphologic dysplasia in hematopoietic lineages, and a variable risk of progression to acute myeloid leukemia. Significant advances in the understanding of MDS have been made in recent years, largely due to the implementation of molecular tools. Latin America is a highly diverse region, both ethnically and racially, and often faces resource limitations that challenge the broad applicability of recent advances in MDS. In this review, we discuss the key genes implicated in the pathogenesis and classification of MDS, and their relevance to diagnosis, prognosis, and potential therapeutic targets. We also explore the challenges associated with the identification of germline predisposition to MDS in Latin America and discuss the current availability and limitations of molecular diagnostic tools in the region.

21 April 2026 in Cancer Medicine
Verified
Journal Article
Open access
CMClaudia Alejandra Martin
Claudia Alejandra Martin
CBCatalina Bono
Catalina Bono
JMJuliana Mandrile
Juliana Mandrile
CKChristine Susana Mercedes Kunst
Christine Susana Mercedes Kunst
ABAdriana Elizabeth Borello
Adriana Elizabeth Borello
Danilo Guillermo CeschinDanilo Guillermo Ceschin
Danilo Guillermo Ceschin
Hereditary breast and ovarian cancer (HBOC) syndromes are strongly associated with germline pathogenic variants. While genetic testing historically focused on BRCA1/2, multigene panels have revealed clinically relevant variants in numerous non‐BRCA genes. However, data on the spectrum and prevalence of these variants remain limited in Argentina, particularly in regions with distinctive admixture patterns. This study aimed to determine the frequency and spectrum of pathogenic and likely pathogenic variants (P/LPVs) in non‐BRCA genes among patients with a personal and/or family history of breast or ovarian cancer evaluated in Córdoba, Argentina. We conducted a retrospective analysis of 283 individuals tested within the Oncogenetics Program at Hospital Privado Universitario de Córdoba between 2016 and 2022 using multigene next‐generation sequencing panels and Sanger sequencing according to contemporary clinical criteria. P/LPVs were identified in 85 individuals (30.0%, 95% CI: 24.7–35.8), with non‐BRCA genes accounting for 32 P/LPVs (11.3%, 95% CI: 7.9–15.6 of the cohort). The most prevalent non‐BRCA genes were PALB2 (4.59%, 95% CI: 2.5–7.7) and CHEK2 (2.47%, 95% CI: 1.0–5.0), followed by TP53, MUTYH, and ATM. Notably, the PALB2 c.1653T>A variant was identified in five unrelated families, representing a recurrent variant compatible with a possible founder effect in this population. Overall, these findings highlight a substantial contribution of non‐BRCA P/LPVs—particularly PALB2—in this Córdoba‐based HBOC cohort. Post hoc analyses suggested sufficient statistical sensitivity to detect the observed differences; however, results should be interpreted considering the retrospective, single‐center design. These findings support the clinical value of incorporating non‐BRCA genes into multigene testing strategies in Argentina and underscore the need for larger multi‐center studies to confirm these observations and refine genetic counseling and surveillance strategies in Latin American populations.

21 April 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
ABAna Lisa Basquiera
Ana Lisa Basquiera
VAVerónica Andreoli
Verónica Andreoli
SGSofía Grille
Sofía Grille
CBCarolina B. Belli
Carolina B. Belli
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematological malignancies characterized by ineffective hematopoiesis, resulting in cytopenias, morphologic dysplasia in hematopoietic lineages, and a variable risk of progression to acute myeloid leukemia. Significant advances in the understanding of MDS have been made in recent years, largely due to the implementation of molecular tools. Latin America is a highly diverse region, both ethnically and racially, and often faces resource limitations that challenge the broad applicability of recent advances in MDS. In this review, we discuss the key genes implicated in the pathogenesis and classification of MDS, including those related to germline predisposition syndromes, and their relevance to diagnosis, prognosis, and therapeutic decision-making. We also highlight research efforts from Latin America and present the results of a survey assessing the availability of molecular tools in Latin American centers.